This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Investigations

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Initial assessment refers to assessment carried out in any setting by a healthcare professional without specific training in managing LUTS in men (1)

  • at initial assessment, ask men with bothersome LUTS to complete a urinary frequency volume chart

  • offer men with LUTS a urine dipstick test to detect blood, glucose, protein, leucocytes and nitrites

  • NICE suggest that men with LUTS a serum creatinine test at initial assessment (plus estimated glomerular filtration rate [eGFR] calculation) only if suspect renal impairment (for example, the man has a palpable bladder, nocturnal enuresis, recurrent urinary tract infections or a history of renal stones)
    • - 80% of renal function must be lost before creatinine rises
  • cystoscopy should not be routinely offered to men with uncomplicated LUTS (that is, without evidence of bladder abnormality) at initial assessment

Notes:

  • other investigations often undertaken in primary care include:
    • FBC - especially if contemplating surgery
    • MSU - microscopy and culture to exclude UTI
    • prostate specific antigen (PSA)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.